QNTM News - Candlesense

Quantum BioPharma Announces Corporate Updates

TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedic...

Corporate

6 days ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedic...

What are the potential upside and downside scenarios for Lucid‑MS based on historical success rates of Phase 2 MS trials? How does the recent news compare with peers’ recent Phase 2 announcements in neuro‑degenerative or MS space? What are the potential dilution effects from any financing associated with the trial and manufacturing partnership?

Clinical trials

16 days ago